Orion Oyj (ORINF)
USD 48.65
(0.0%)
USD 48.65
(0.0%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 171 Million EUR | -13.11% |
| 2022 | 196.8 Million USD | 73.14% |
| 2021 | 113.66 Million EUR | -7.1% |
| 2020 | 122.35 Million EUR | 1726.19% |
| 2019 | 6.7 Million EUR | 1016.67% |
| 2018 | 600 Thousand EUR | -99.6% |
| 2017 | 149.7 Million EUR | 0.13% |
| 2016 | 149.5 Million EUR | -22.42% |
| 2015 | 192.7 Million EUR | -8.23% |
| 2014 | 210 Million EUR | -9.99% |
| 2013 | 233.3 Million EUR | 117.23% |
| 2012 | 107.4 Million EUR | 62.73% |
| 2011 | 66 Million EUR | -24.57% |
| 2010 | 87.5 Million EUR | -19.5% |
| 2009 | 108.7 Million EUR | -1.09% |
| 2008 | 109.9 Million EUR | 9058.33% |
| 2007 | 1.2 Million EUR | -84.0% |
| 2006 | 7.5 Million EUR | -67.81% |
| 2005 | 23.3 Million EUR | -58.32% |
| 2004 | 55.9 Million EUR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q3 | 253.3 Million EUR | -100.0% |
| 2024 Q2 | 234.1 Million EUR | 41.71% |
| 2024 Q1 | 178.25 Million EUR | -0.66% |
| 2023 Q3 | 186.89 Million USD | -6.47% |
| 2023 Q2 | 199.82 Million USD | -2.81% |
| 2023 Q1 | 205.59 Million USD | 0.05% |
| 2023 Q4 | 183.55 Million EUR | -1.79% |
| 2023 FY | 171 Million EUR | -13.11% |
| 2022 Q4 | 205.48 Million USD | 5.95% |
| 2022 FY | 196.8 Million USD | 73.14% |
| 2022 Q1 | 86.6 Million EUR | -17.29% |
| 2022 Q2 | 213.05 Million EUR | 146.03% |
| 2022 Q3 | 193.94 Million EUR | -8.97% |
| 2021 Q2 | 124.4 Million EUR | 0.81% |
| 2021 Q4 | 104.7 Million EUR | 0.0% |
| 2021 Q3 | 104.7 Million EUR | -15.84% |
| 2021 Q1 | 123.4 Million EUR | 16.97% |
| 2021 FY | 113.66 Million EUR | -7.1% |
| 2020 Q1 | 105.9 Million EUR | 1480.6% |
| 2020 FY | 122.35 Million EUR | 1726.19% |
| 2020 Q2 | 106 Million EUR | 0.09% |
| 2020 Q3 | 105.4 Million EUR | -0.57% |
| 2020 Q4 | 105.5 Million EUR | 0.09% |
| 2019 FY | 6.7 Million EUR | 1016.67% |
| 2019 Q4 | 6.7 Million EUR | 31.37% |
| 2019 Q2 | 5 Million EUR | -7.41% |
| 2019 Q3 | 5.1 Million EUR | 2.0% |
| 2019 Q1 | 5.4 Million EUR | 800.0% |
| 2018 Q1 | 150.4 Million EUR | 0.07% |
| 2018 FY | 600 Thousand EUR | -99.6% |
| 2018 Q4 | 600 Thousand EUR | 0.0% |
| 2018 Q3 | 600 Thousand EUR | 20.0% |
| 2018 Q2 | 500 Thousand EUR | -99.67% |
| 2017 Q1 | 150.3 Million EUR | 0.07% |
| 2017 FY | 149.7 Million EUR | 0.13% |
| 2017 Q4 | 150.3 Million EUR | -0.07% |
| 2017 Q3 | 150.4 Million EUR | 0.07% |
| 2017 Q2 | 150.3 Million EUR | 0.0% |
| 2016 Q1 | 175.7 Million EUR | -1.24% |
| 2016 FY | 149.5 Million EUR | -22.42% |
| 2016 Q4 | 150.2 Million EUR | 0.07% |
| 2016 Q3 | 150.1 Million EUR | -14.57% |
| 2016 Q2 | 175.7 Million EUR | 0.0% |
| 2015 Q3 | 200.2 Million EUR | -2.01% |
| 2015 FY | 192.7 Million EUR | -8.23% |
| 2015 Q4 | 177.9 Million EUR | -11.14% |
| 2015 Q2 | 204.3 Million EUR | -0.87% |
| 2015 Q1 | 206.1 Million EUR | -1.86% |
| 2014 Q2 | 227.4 Million EUR | -0.83% |
| 2014 Q3 | 217.5 Million EUR | -4.35% |
| 2014 Q4 | 210 Million EUR | -3.45% |
| 2014 FY | 210 Million EUR | -9.99% |
| 2014 Q1 | 229.3 Million EUR | -1.71% |
| 2013 Q2 | 250.5 Million EUR | 142.26% |
| 2013 Q1 | 103.4 Million EUR | -3.72% |
| 2013 FY | 233.3 Million EUR | 117.23% |
| 2013 Q4 | 233.3 Million EUR | -3.11% |
| 2013 Q3 | 240.8 Million EUR | -3.87% |
| 2012 Q3 | 119.7 Million EUR | -5.97% |
| 2012 Q2 | 127.3 Million EUR | -5.0% |
| 2012 Q1 | 134 Million EUR | 103.03% |
| 2012 FY | 107.4 Million EUR | 62.73% |
| 2012 Q4 | 107.4 Million EUR | -10.28% |
| 2011 Q2 | 82.6 Million EUR | -5.6% |
| 2011 Q3 | 76.8 Million EUR | -7.02% |
| 2011 Q4 | 66 Million EUR | -14.06% |
| 2011 Q1 | 87.5 Million EUR | 0.0% |
| 2011 FY | 66 Million EUR | -24.57% |
| 2010 FY | 87.5 Million EUR | -19.5% |
| 2010 Q3 | 98.1 Million EUR | -5.4% |
| 2010 Q4 | 87.5 Million EUR | -10.81% |
| 2010 Q1 | 108.8 Million EUR | 0.09% |
| 2010 Q2 | 103.7 Million EUR | -4.69% |
| 2009 FY | 108.7 Million EUR | -1.09% |
| 2009 Q4 | 108.7 Million EUR | 0.0% |
| 2008 FY | 109.9 Million EUR | 9058.33% |
| 2007 FY | 1.2 Million EUR | -84.0% |
| 2006 Q4 | 7.5 Million EUR | 0.0% |
| 2006 FY | 7.5 Million EUR | -67.81% |
| 2005 FY | 23.3 Million EUR | -58.32% |
| 2004 FY | 55.9 Million EUR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| AstraZeneca PLC | 22.33 Billion USD | 99.234% |
| Bristol-Myers Squibb Company PFD CONV 2 | 38.18 Billion USD | 99.552% |
| CSPC Pharmaceutical Group Limited | 107.05 Million USD | -59.727% |
| Clarus Therapeutics Holdings, Inc. | - USD | -Infinity% |
| Novartis AG | 20.03 Billion USD | 99.146% |
| PT Kalbe Farma Tbk. | 19.39 Million USD | -781.812% |